Organization | Meda Pharmaceuticals

Meda Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Solna Sweden (1995)

Status: Acquired by Mylan (2016)

Organization Overview

First Clinical Trial

2018

NCT03599791

First Marketed Drug

1995

acetylsalicylic acid (aspirin)

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MEDA Pharma GmbH & Co. KG | Meda Pharma GmbH & Co. KG (A Mylan Company) | MEDA PHARMS

Active Ingredients

Marketed Drugs (9)

Key: Meda Pharmaceuticals (8) Acquired (1)

acetylsalicylic acid (aspirin) (1960)

azelastine (astelin) (2009)

butabarbital (neonal) (1978)

carisoprodol (soma) (1960)

codeine (Phenergan) (1960)

mesalamine (rowasa) (1990)

metoclopramide (reglan) (2005)

potassium iodide (thyro-block) (1979 NDA)

sildenafil (viagra) (2009)

Drugs in Phase 4 Trials (4)

Key: Meda Pharmaceuticals (1) Acquired (3)

azelastine (astelin) (3 trials)

gabapentin (neurontin) (1 trial)

oxycodone (oxycontin) (1 trial)

varenicline (chantix) (10 trials)

Drugs in Phase 3 Trials (16)

Key: Meda Pharmaceuticals (2) Acquired (14)

acetaminophen (tylenol) (1 trial)

acetylsalicylic acid (aspirin) (2 trials)

adalimumab (humira) (1 trial)

berberine (3 trials)

cholesterol (3 trials)

dexloxiglumide (1 trial)

fluticasone (cutivate) (1 trial)

glucosamine (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

lactose (1 trial)

megestrol (megace) (2 trials)

plantago ovata (2 trials)

policosanol (4 trials)

ribavirin (virazole) (1 trial)

Silibinin (4 trials)

silymarin (4 trials)

Drugs in Phase 2 Trials (8)

Key: Meda Pharmaceuticals (2) Acquired (6)

agen2034 (1 trial)

covid-evax (1 trial)

cr6086 (2 trials)

isphagula husk (1 trial)

mometasone (elocon) (1 trial)

olopatadine (patanol) (1 trial)

simpanicline (2 trials)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (1)

Key: Meda Pharmaceuticals (0) Acquired (1)

hemicellulose (1 trial)

Indications

Approved Indications

Anemia

Radioactive Pollutants

Experimental Indications (Clinical Trials, Phases 1-4)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 41
# of Trial APIs: 29